Is MNKD a good stock to buy? We came across a bullish thesis on MannKind Corporation on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on MNKD. MannKind Corporation’s share was trading at $3.8400 as of June 24th. MNKD’s trailing and forward P/E were 178.00 and 40.49 respectively according to Yahoo Finance.
Sergey Nivens/Shutterstock.com
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. The thesis centers on the company’s transformation into a diversified healthcare business supported by three revenue streams: Afrezza inhaled insulin, Furoscix for heart failure patients, and high-margin royalties from Tyvaso DPI through its partnership with United Therapeutics.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Management has strategically shifted away from the competitive diabetes market toward pulmonary and cardiovascular diseases, while the acquisition of scPharmaceuticals has broadened the company’s revenue base and strengthened its commercial footprint. The company’s proprietary Technosphere platform, protected by patents extending into the late 2030s and supported by specialized manufacturing capabilities, enables the development of inhaled therapies designed to improve efficacy and reduce side effects associated with conventional treatments.
Clinical results have been encouraging across the portfolio, with pediatric Afrezza demonstrating strong glucose control and safety, Furoscix matching hospital IV performance in treating fluid overload, and Nintedanib DPI showing favorable tolerability in early studies for idiopathic pulmonary fibrosis. Several near-term catalysts could drive a significant rerating, including FDA decisions on pediatric Afrezza and the Furoscix ReadyFlow Autoinjector, continued growth in Tyvaso DPI royalties, and advancing clinical data from the pulmonary pipeline.
Financially, MannKind generated $349 million in 2025 revenue, grew sales by 22%, eliminated its remaining debt, and held $134 million in cash as of March 2026, providing flexibility to fund growth initiatives. Using a risk-adjusted sum-of-the-parts valuation, the analysis derives a target price of $8.50 per share, implying approximately 134% upside from current levels, while successful execution across regulatory and clinical milestones could support a blue-sky valuation range of $10 to $12 per share.
Previously, we covered a bullish thesis on AbCellera Biologics Inc. (ABCL) by Jack Prescott in January 2025, which highlighted the company’s AI-driven antibody discovery platform, asset-light royalty model, strong balance sheet, and partnership-driven pipeline. ABCL’s stock price has appreciated by approximately 105.10% since our coverage. BioEquity Watch shares a similar view but emphasizes MannKind Corporation’s diversified rare-disease platform, royalty-backed cash flows and commercial product growth.
MannKind Corporation is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 25 hedge fund portfolios held MNKD at the end of the first quarter which was 39 in the previous quarter. While we acknowledge the risk and potential of MNKD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MNKD and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
